TY - JOUR
T1 - Developments in the diagnosis and treatment of primary CNS lymphoma
T2 - A prospective series
AU - Neuwelt, Edward A.
AU - Frenkel, Eugene P.
AU - Gumerlock, Mary Kay
AU - Braziel, Rita
AU - Dana, Bruce
AU - Hill, Suellen A.
PY - 1986/10/15
Y1 - 1986/10/15
N2 - Current experience with 12 patients studied prospectively suggests a new approach in the diagnosis and treatment of primary central nervous system (CNS) lymphoma, integrating the techniques of needle brain biopsy, immunohistochemicai staining for monoclonal antibody and chemotherapeutic drug delivery in association with blood‐brain barrier modification. Computed tomography (CT)‐guided needle biopsy of deep parenchymal lesions contributed to the diagnosis in six patients. Immunohistochemicai staining methods detected monoclonal immunoglobulins in those patients so tested. Following diagnosis, the patients have been treated with multi‐agent chemotherapy in conjunction with osmotic blood‐brain barrier modification (five without antecedent cranial irradiation) with an initial complete response rate by CT scan in nine patients, a median follow‐up of 19 months from diagnosis, and a 1‐year survival of 75%. This experience emphasizes the value of CT‐guided stereotaxic or CT‐guided needle biopsy, which limits the need for therapy without a diagnosis or the need for a major craniotomy in what are commonly deep, paraventricular lesions. Immunoperoxidase cytochemical stains can detect monoclonal immunoglobulin characteristic of CNS B‐cell malignant lymphomas and provide an important diagnostic aid when only modest quantities of tissue or cells are obtained. Finally, chemotherapy administered in conjunction with osmotic blood‐brain barrier modification results in a clinical response rate and survival that are at least as effective as radiotherapy as a primary therapeutic modality.
AB - Current experience with 12 patients studied prospectively suggests a new approach in the diagnosis and treatment of primary central nervous system (CNS) lymphoma, integrating the techniques of needle brain biopsy, immunohistochemicai staining for monoclonal antibody and chemotherapeutic drug delivery in association with blood‐brain barrier modification. Computed tomography (CT)‐guided needle biopsy of deep parenchymal lesions contributed to the diagnosis in six patients. Immunohistochemicai staining methods detected monoclonal immunoglobulins in those patients so tested. Following diagnosis, the patients have been treated with multi‐agent chemotherapy in conjunction with osmotic blood‐brain barrier modification (five without antecedent cranial irradiation) with an initial complete response rate by CT scan in nine patients, a median follow‐up of 19 months from diagnosis, and a 1‐year survival of 75%. This experience emphasizes the value of CT‐guided stereotaxic or CT‐guided needle biopsy, which limits the need for therapy without a diagnosis or the need for a major craniotomy in what are commonly deep, paraventricular lesions. Immunoperoxidase cytochemical stains can detect monoclonal immunoglobulin characteristic of CNS B‐cell malignant lymphomas and provide an important diagnostic aid when only modest quantities of tissue or cells are obtained. Finally, chemotherapy administered in conjunction with osmotic blood‐brain barrier modification results in a clinical response rate and survival that are at least as effective as radiotherapy as a primary therapeutic modality.
UR - http://www.scopus.com/inward/record.url?scp=0022486416&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022486416&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19861015)58:8<1609::AID-CNCR2820580805>3.0.CO;2-7
DO - 10.1002/1097-0142(19861015)58:8<1609::AID-CNCR2820580805>3.0.CO;2-7
M3 - Article
C2 - 3756785
AN - SCOPUS:0022486416
SN - 0008-543X
VL - 58
SP - 1609
EP - 1620
JO - Cancer
JF - Cancer
IS - 8
ER -